Table 4.

ORs and 95% CI for MTHFR polymorphisms with risk of breast cancer stratified by supplement use in the Long Island Breast Cancer Study Project, 1996-1997

GenotypeNo. cases (%)No. controls (%)OR (95% CI) *OR (95% CI)
677C>T
    Supplement use = yes
        677CC216 (40.2)221 (38.3)1.0 (referent)1.0 (referent)
        677CT222 (41.3)271 (47.0)0.84 (0.65-1.09)1.18 (0.82-1.68)
        677TT99 (18.4)85 (14.7)1.20 (0.85-1.70)0.83 (0.64-1.09)
        P, trend 0.680.74
    Supplement use = no
        677CC174 (34.1)213 (41.7)1.0 (referent)1.0 (referent)
        677CT247 (48.4)230 (45.0)1.33 (1.02-1.75)1.36 (1.03-1.81)
        677TT89 (17.5)68 (13.3)1.55 (1.07-2.27)1.70 (1.14-2.52)
        P, trend0.0070.005
1298A>C
    Supplement use = yes
        1298AA275 (51.3)282 (49.1)1.00 (referent)1.00 (referent)
        1298AC214 (39.9)235 (40.9)0.94 (0.73-1.20)0.93 (0.72-1.20)
        1298CC47 (8.8)57 (9.9)0.81 (0.53-1.24)0.83 (0.54-1.29)
        P, trend0.340.38
    Supplement use = no
        1298AA274 (53.7)249 (48.4)1.00 (referent)1.00 (referent)
        1298AC198 (38.8)214 (41.6)0.85 (0.66-1.11)0.80 (0.61-1.05)
        1298CC38 (7.5)51 (9.9)0.71 (0.45-1.12)0.62 (0.38-1.01)
        P, trend0.090.02
  • * Adjusted for age.

  • Adjusted for age, family history of breast cancer in first-degree relative, history of benign breast disease, educational attainment, body mass index at age 20, and kilocalories per day.

  • P value for trend for categorical variables.